Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | GSK3B | P49841 | 10/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17824310 | 0.86 | LMNA (0.53) | LMNAHTTTSHRKMT2ARAB9A | |
| SCHEMBL17824315 | 0.86 | ADORA2A (0.54) | LMNAHTTTSHRKMT2ACYP1A2 | |
| SCHEMBL17824318 | 0.82 | RAB9A (0.53) | LMNAHTTTSHRKMT2ARAB9A | |
| SCHEMBL17824312 | 0.82 | RAB9A (0.64) | LMNAHTTTSHRKMT2ACYP1A2 | |
| SCHEMBL17824297 | 0.82 | ALDH1A1 (0.67) | LMNAHTTTSHRKMT2APOLB | |
| SCHEMBL17824317 | 0.81 | ALDH1A1 (0.59) | LMNAHTTTSHRKMT2ARAB9A | |
| SCHEMBL17824306 | 0.80 | MAPT (0.71) | TSHRCYP2C19RAB9ASMN1; SMN2 | |
| SCHEMBL12495433 | 0.80 | ALDH1A1 (0.72) | LMNAHTTTSHRGSK3BKMT2A | |
| SCHEMBL12497263 | 0.80 | LMNA (0.69) | LMNAHTTTSHRGSK3BKMT2A | |
| SCHEMBL3430135 | 0.80 | LMNA (1.00) | LMNAHTTTSHRGSK3BKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | HERIOT-WATT UNIVERSITY (GB) | 2017-12-21 | — | — | US | disclosed |
| EP-3230275-A1 | PRO-SURVIVAL COMPOUNDS | University Court of The University of Glasgow (GB) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
| WO-2016092327-A1 | PRO-SURVIVAL COMPOUNDS | UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362184-A1 | PRO-SURVIVAL COMPOUNDS | MCL1, MKI67, MORF4L1 | LMNA 301/4885HTT 3064/4885TSHR 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.